Aplaviroc

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Script error: No such module "TemplatePar".Template:Infobox drug/maintenance categories

Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines[1] developed for the treatment of HIV infection.[2][3] It was developed by GlaxoSmithKline.

In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns.[4][5] Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development;[6] the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.[7]

See also

References

<templatestyles src="Reflist/styles.css" />

  1. Script error: No such module "Citation/CS1".
  2. Script error: No such module "citation/CS1".
  3. Script error: No such module "Citation/CS1".
  4. Script error: No such module "citation/CS1".
  5. Script error: No such module "Citation/CS1".
  6. Script error: No such module "citation/CS1".
  7. Script error: No such module "Citation/CS1".

Script error: No such module "Check for unknown parameters".

Further reading

<templatestyles src="Refbegin/styles.css" />

  • Script error: No such module "Citation/CS1".

Script error: No such module "Navbox". Template:Chemokine receptor modulators

Template:Antiinfective-drug-stub